For a drug designed to change how the brain functions, reaching the brain is only part of the story. Understanding what happens once it gets there can help shape the path into clinical trials.
That is the focus of new preclinical findings announced by Enveric Biosciences on November 4. The company reported that its lead neuroplastogen candidate, EB-003, produced measurable changes in brain-wave activity in mice, with a pattern differentiated from the classic psychedelic dimethyltryptamine, or DMT.
The study also offers Enveric a potential tool for its planned first human trials: a way to connect exposure to EB-003 with an observable response in the brain.
Following the electrical signal
The researchers used quantitative electroencephalography, or qEEG, to record brain activity continuously across a broad range of frequency bands. DMT was included as a comparator.
EB-003 modulated brain-wave oscillations in the prefrontal and parietal regions of the cortex. According to Enveric, those changes provide functional evidence that the compound reaches the central nervous system and affects brain activity.
For EB-003’s development, this adds another layer of information about how the molecule behaves. The study moves the investigation into measurable changes in cortical electrical function, giving researchers a potential signal to follow as the program advances.
The distinction matters because a brain-wave response can help establish that a compound is biologically active. Whether that activity translates into therapeutic benefit remains a question for clinical research.
A different profile from DMT
Enveric is developing EB-003 with the aim of promoting neuroplasticity without hallucinogenic effects. The candidate is designed to engage both 5-HT2A and 5-HT1B receptors, and the company is investigating its potential for psychiatric and neurological disorders.
The latest study examined how its effects on brain electrical activity compared with those of DMT.
Enveric reported that DMT induced notable epileptic-like EEG activity and acute body spasms under the study conditions. EB-003 did not produce similar findings. The company also reported that EB-003 did not induce abnormal epileptiform activity or disruptive sedation patterns.
Those observations add to the preclinical evidence distinguishing the two compounds. They also require careful interpretation: the comparison describes what researchers observed in this mouse study. It does not establish comparative safety in people or determine the risks of DMT across other settings.
Likewise, a differentiated qEEG profile does not establish what a person would experience after receiving EB-003. Its intended non-hallucinogenic profile will need to be evaluated during human development.
For a field exploring how compounds related to psychedelics might be developed into new medicines, the findings offer a more detailed view of one candidate’s functional effects.
Bringing a measurable response into Phase 1
The potential clinical use of qEEG is a central part of the announcement.
Enveric plans to evaluate whether the technique can serve as a pharmacodynamic biomarker in EB-003’s first-in-human program. In practical terms, that would mean using changes in brain electrical activity as a measurable indicator of the drug’s effects.
Alongside safety assessments and measurements of drug exposure, qEEG could help researchers investigate how the brain responds at different doses.
“…the ability to correlate drug exposure to changes in brain activity on qEEG could help us identify biologically active doses,” said Joseph Tucker, Ph.D., Enveric’s director and chief executive officer.
That could help inform which doses warrant further investigation. A biologically active dose, however, is a starting point for clinical decision-making. Establishing an effective treatment would require studies designed to assess patient outcomes.
The mouse findings support taking this measurement approach into human research. Whether the signal translates reliably to people, and how useful it proves for dose selection, remain open questions.
What the findings add
EB-003 remains a preclinical candidate advancing toward a planned Phase 1 trial. The new study adds evidence of functional activity in the brain and provides a possible method for tracking that activity during early human testing.
The announcement does not include detailed numerical qEEG results or a full study report. That limits independent assessment of the magnitude of the effects and the strength of the comparison with DMT.
Even with those limits, the developmental question is clear. Enveric now has a potential electrical signal to investigate as EB-003 moves toward the clinic. Following that signal in humans could help the company understand how drug exposure relates to brain activity and use that information to shape subsequent trials.